Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
BPMC [NASD]
Blueprint Medicines Corporation
Healthcare | Biotechnology | USA
statements
Index- P/E18.81 EPS (ttm)5.25 Insider Own0.70% Shs Outstand56.08M Perf Week1.38%
Market Cap5.60B Forward P/E- EPS next Y-5.30 Insider Trans-31.40% Shs Float54.61M Perf Month2.11%
Income313.90M PEG0.84 EPS next Q-1.76 Inst Own- Short Float5.24% Perf Quarter-7.90%
Sales793.70M P/S7.06 EPS this Y176.90% Inst Trans1.15% Short Ratio5.99 Perf Half Y33.52%
Book/sh26.21 P/B3.77 EPS next Y18.70% ROA25.10% Target Price117.29 Perf Year73.04%
Cash/sh15.38 P/C6.43 EPS next 5Y22.27% ROE31.00% 52W Range43.29 - 125.61 Perf YTD-11.91%
Dividend- P/FCF14.59 EPS past 5Y30.80% ROI20.90% 52W High-22.80% Beta0.73
Dividend %- Quick Ratio7.00 Sales past 5Y133.60% Gross Margin99.90% 52W Low123.99% ATR4.75
Employees429 Current Ratio7.10 Sales Q/Q-33.80% Oper. Margin38.90% RSI (14)45.91 Volatility3.96% 4.80%
OptionableYes Debt/Eq0.00 EPS Q/Q-13.40% Profit Margin39.50% Rel Volume0.47 Prev Close98.79
ShortableYes LT Debt/Eq0.00 EarningsFeb 17 BMO Payout0.00% Avg Volume478.07K Price96.96
Recom1.90 SMA20-2.05% SMA50-7.12% SMA2007.92% Volume21,100 Change-1.85%
Dec-03-20Initiated Stifel Hold $110
Nov-02-20Reiterated H.C. Wainwright Buy $110 → $135
Nov-02-20Downgrade Jefferies Buy → Hold $90 → $96
Oct-30-20Downgrade Morgan Stanley Overweight → Equal-Weight $112
Jul-15-20Reiterated H.C. Wainwright Buy $66 → $110
May-05-20Initiated Barclays Equal Weight $59
Mar-17-20Upgrade BMO Capital Markets Market Perform → Outperform $74 → $89
Jan-28-20Initiated BMO Capital Markets Market Perform
Jan-27-20Initiated BMO Capital Markets Market Perform
Nov-06-19Upgrade Raymond James Outperform → Strong Buy $106 → $112
Oct-22-19Initiated JMP Securities Mkt Outperform $106
Oct-03-19Initiated H.C. Wainwright Buy $100
Sep-12-19Upgrade Raymond James Mkt Perform → Outperform
Aug-29-19Initiated Piper Jaffray Neutral $85
Aug-15-19Resumed Raymond James Mkt Perform
Jul-18-19Initiated Deutsche Bank Buy $110
May-23-19Resumed Goldman Buy $125
Apr-03-19Initiated Morgan Stanley Overweight $112
Sep-25-18Initiated Leerink Partners Outperform
Dec-11-17Reiterated Goldman Buy $82 → $99
Mar-03-21 08:00AM  
Blueprint Medicines Announces EMA Validation of Type II Variation Marketing Authorization Application for AYVAKYT® (avapritinib) for the Treatment of Advanced Systemic Mastocytosis
PR Newswire
Feb-27-21 09:23AM  
15 Fastest Growing Biotech Companies in the US
Insider Monkey
Feb-17-21 07:36AM  
Recap: Blueprint Medicines Q4 Earnings
Benzinga +7.56%
07:00AM  
Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results
PR Newswire
06:30AM  
Blueprint Medicines Corp. to Host Earnings Call
ACCESSWIRE
Feb-10-21 08:00AM  
Blueprint Medicines to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 17, 2021
PR Newswire
Feb-05-21 04:01PM  
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire
Jan-22-21 10:18AM  
AzurRx (AZRX) Starts Dosing in Pancreatic Insufficiency Study
Zacks
Jan-20-21 12:00PM  
Blueprint Medicines (BPMC) Upgraded to Strong Buy: Here's What You Should Know
Zacks
Jan-13-21 09:42AM  
3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic
Zacks
Jan-11-21 11:22AM  
Infrastructure and Energy Alternatives, Carrols Restaurant, Moderna, Blueprint Medicines and Halozyme Therapeutics highlighted as Zacks Bull and Bear of the Day
Zacks
08:05AM  
Blueprint Medicines Announces R&D Leadership Transitions
PR Newswire
08:00AM  
Blueprint Medicines Reports Portfolio Milestones and Outlines 2021 Roadmap for Precision Medicine Leadership
PR Newswire
Jan-08-21 09:05AM  
3 Biotech Stocks Worth Adding to Your Portfolio in 2021
Zacks
Jan-05-21 04:01PM  
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire
Jan-04-21 09:30AM  
Axsome's (AXSM) Migraine Drug Shows Long-Term Safety in Study
Zacks -6.76%
Dec-31-20 08:46AM  
Amarin (AMRN) Surges: Stock Moves 9% Higher
Zacks
Dec-30-20 11:33PM  
Is Blueprint Medicines Corporation's (NASDAQ:BPMC) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Simply Wall St.
Dec-22-20 05:08PM  
Is BPMC A Good Stock To Buy According To Hedge Funds?
Insider Monkey
Dec-21-20 01:59PM  
Blueprint Medicines (BPMC) Rises 40% in Past 3 Months: Here's Why
Zacks
Dec-17-20 08:00AM  
Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT (avapritinib) for the Treatment of Advanced Systemic Mastocytosis
PR Newswire
Dec-07-20 08:00AM  
Blueprint Medicines Data Presented at 62nd ASH Annual Meeting and Exposition Highlight Broad Commitment to Advance Patient Care in Systemic Mastocytosis
PR Newswire
Dec-04-20 04:01PM  
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire
Dec-02-20 10:50AM  
Blueprint Medicines' (BPMC) Gavreto Approved for Thyroid Cancer
Zacks
Dec-01-20 03:15PM  
Blueprint Medicines Announces FDA Approval of GAVRETO (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer
PR Newswire
Nov-23-20 08:00AM  
Blueprint Medicines To Present Broad Range of Data Reinforcing Commitment to Advance Patient Care in Systemic Mastocytosis at 62nd ASH Annual Meeting and Exposition
PR Newswire
Nov-03-20 04:05PM  
Was The Smart Money Right About Loading Up On Blueprint Medicines Corporation (BPMC)?
Insider Monkey
04:01PM  
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire
Nov-01-20 07:43AM  
Blueprint Medicines Corporation (NASDAQ:BPMC) Just Beat EPS By 19%: Here's What Analysts Are Forecasting For Next Year
Simply Wall St.
Oct-30-20 08:09AM  
The Daily Biotech Pulse: Novavax Vaccine Data, Axovant Flags Delay In Parkinson's Study, 2 Biotechs Make Wall Street Debuts
Benzinga
Oct-29-20 11:17AM  
Blueprint Medicines (BPMC) Q3 Earnings Beat, Revenues Rise Y/Y
Zacks
08:35AM  
Blueprint Medicines (BPMC) Q3 Earnings and Revenues Surpass Estimates
Zacks
07:38AM  
Blueprint Medicines: Q3 Earnings Insights
Benzinga
07:00AM  
Blueprint Medicines Reports Third Quarter 2020 Financial Results
PR Newswire
06:30AM  
Blueprint Medicines Corp. to Host Earnings Call
ACCESSWIRE
Oct-26-20 11:54PM  
5 Healthcare Stocks the Experts at Aquilo Capital Management Are Buying (1 Has Gained 88% This Month)
Insider Monkey
Oct-22-20 08:00AM  
Blueprint Medicines to Report Third Quarter 2020 Financial Results on Thursday, October 29, 2020
PR Newswire
Oct-02-20 04:01PM  
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire
Sep-30-20 07:17AM  
Imagine Holding Blueprint Medicines (NASDAQ:BPMC) Shares While The Price Zoomed 333% Higher
Simply Wall St.
Sep-29-20 11:46AM  
Blueprint Medicines Rises YTD on Robust Ayvakit Progress
Zacks
Sep-28-20 12:38PM  
Blueprint Medicines' Gist Drug Ayvakyt Gets EU Approval
Zacks
Sep-25-20 11:46AM  
Blueprint Medicines Announces European Commission Approval of AYVAKYT® (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors
PR Newswire
Sep-23-20 12:54PM  
Blueprint Medicines Up on Positive Top-Line Data From SM Study
Zacks
09:30AM  
Company News for Sep 23, 2020
Zacks
08:05AM  
The Daily Biotech Pulse: Coronavirus Vaccine Updates From J&J & MediciNova, Australian Regulatory Nod For GW Pharma
Benzinga
Sep-22-20 04:23PM  
Blueprint Medicines Reports Positive Test Results For Rare Disease Treatment; BPMC Stock Jumps
Investor's Business Daily +13.03%
07:00AM  
Blueprint Medicines Announces Positive Top-line Results from EXPLORER and PATHFINDER Trials of AYVAKIT (avapritinib) in Patients with Advanced Systemic Mastocytosis
PR Newswire
Sep-20-20 08:25AM  
Blueprint Medicines Reports ARROW Trial Data at ESMO Virtual Congress 2020 Demonstrating Durable Clinical Benefits of GAVRETO (Pralsetinib) in Patients with Advanced RET-Mutant Medullary Thyroid Cancer
PR Newswire
Sep-17-20 08:00AM  
Blueprint Medicines Presents Foundational Preclinical Data for BLU-945 Showing Robust Anti-Tumor Activity in Treatment-Resistant EGFR-Mutated Lung Cancer at ESMO Virtual Congress 2020
PR Newswire
Sep-13-20 07:27AM  
Is Blueprint Medicines a Good Biotech Stock to Buy Now?
Motley Fool
Sep-09-20 08:29PM  
Blueprint Medicines (BPMC): Hedge Fund Sentiment Reaches Another All Time High
Insider Monkey
04:01PM  
Blueprint Medicines to Present at 18th Annual Morgan Stanley Global Healthcare Conference
PR Newswire
Sep-04-20 07:00PM  
Blueprint Medicines Announces FDA Approval of GAVRETO (pralsetinib) for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
PR Newswire
08:00AM  
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire
Sep-01-20 08:00AM  
Blueprint Medicines Strengthens Leadership with Appointment of Fouad Namouni, M.D., as President, Research & Development
PR Newswire
Aug-29-20 11:31AM  
Why Is Blueprint Medicines (BPMC) Up 0.1% Since Last Earnings Report?
Zacks
Aug-04-20 08:00AM  
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire
Aug-01-20 08:21AM  
Blueprint Medicines (NASDAQ:BPMC) Is In A Strong Position To Grow Its Business
Simply Wall St.
Jul-31-20 11:18AM  
Blueprint Medicines' (BPMC) Q2 Earnings Miss, Revenues Beat
Zacks
Jul-30-20 08:35AM  
Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates
Zacks
07:28AM  
Recap: Blueprint Medicines Q2 Earnings
Benzinga
07:00AM  
Blueprint Medicines Reports Second Quarter 2020 Financial Results
PR Newswire
Jul-24-20 08:30AM  
Blueprint Medicines Receives Positive CHMP Opinion for Avapritinib for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors
PR Newswire
Jul-23-20 08:00AM  
Blueprint Medicines to Report Second Quarter 2020 Financial Results on Thursday, July 30, 2020
PR Newswire
Jul-14-20 05:22PM  
Could A $775 Million Roche-Blueprint Deal Unseat Eli Lilly In Cancer?
Investor's Business Daily
12:23PM  
Blueprint Medicines Inks Deal With Roche Worth Up to $1.7 Billion
Motley Fool
12:22PM  
Blueprint Medicines, Roche to Develop Pralsetinib for Cancer
Zacks
08:28AM  
Blueprint Medicines shares gain on deal with Roche
MarketWatch
08:04AM  
The Daily Biotech Pulse: Blueprint, Roche Ink $1.7B Cancer Drug Collaboration, INmune's Positive Alzheimer's Readout, Edwards, Abbott Settle Patent Lawsuits
Benzinga
06:23AM  
We're Not Very Worried About Blueprint Medicines' (NASDAQ:BPMC) Cash Burn Rate
Simply Wall St.
03:56AM  
Roche gene testing key to $1.7 billion deal for Blueprint cancer drug
Reuters
01:00AM  
Blueprint Medicines Announces Global Collaboration with Roche to Develop and Commercialize Pralsetinib for Patients with RET-Altered Cancers
PR Newswire
Jul-13-20 08:25PM  
Did Hedge Funds Make The Right Call On Blueprint Medicines Corporation (BPMC) ?
Insider Monkey
Jul-02-20 04:01PM  
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire
12:25PM  
Blueprint Medicines Files NDA to FDA for Pralsetinib in MTC
Zacks
Jul-01-20 08:00AM  
Blueprint Medicines Announces Submission of New Drug Application to FDA for Pralsetinib for the Treatment of Advanced RET Mutant and RET Fusion-Positive Thyroid Cancers
PR Newswire
Jun-29-20 06:30PM  
Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST
PR Newswire
Jun-06-20 09:00AM  
Blueprint Medicines Presents Updated Part 1 Data from PIONEER Trial of Avapritinib Showing Robust Reductions in Cutaneous Disease Symptoms in Patients with Indolent Systemic Mastocytosis
PR Newswire
Jun-05-20 11:32AM  
Blueprint Medicines (BPMC) Up 15.5% Since Last Earnings Report: Can It Continue?
Zacks
Jun-03-20 08:00AM  
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire +5.39%
07:11AM  
The Debate Is Over: This Cancer Stock Is Winning the GIST Race
Motley Fool
03:05AM  
Hedge Funds Are Done Buying Blueprint Medicines Corporation (BPMC)
Insider Monkey
May-29-20 01:13PM  
8 Stocks Viking Global Investors Continues to Buy
GuruFocus.com
08:00AM  
Blueprint Medicines Announces Data Presentations at ASCO20 Highlighting Deep, Durable Clinical Activity and Well-Tolerated Safety Profile of Pralsetinib Across Broad Range of RET Fusion-Positive Tumors
PR Newswire
May-27-20 04:30PM  
Blueprint Medicines to Present at Upcoming Investors Conferences
PR Newswire
May-26-20 08:00AM  
Blueprint Medicines to Host Conference Call to Review Updated Clinical Data for Pralsetinib in RET-Altered Cancers on Friday, May 29, 2020
PR Newswire
May-18-20 12:16PM  
Blueprint Medicines Gets CRL for Ayvakit in Fourth-Line Gist
Zacks
May-15-20 12:10PM  
U.S. FDA declines to approve Blueprint's therapy for type of stomach cancer
Reuters
08:00AM  
Blueprint Medicines Receives Complete Response Letter from FDA for Avapritinib New Drug Application for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
PR Newswire
May-14-20 11:29PM  
Edited Transcript of BPMC earnings conference call or presentation 6-May-20 12:30pm GMT
Thomson Reuters StreetEvents
12:00PM  
All You Need to Know About Blueprint Medicines (BPMC) Rating Upgrade to Buy
Zacks
09:00AM  
Blueprint Medicines Announces Data Presentations Highlighting Significant Progress in Advancing RET-Altered Cancer and Systemic Mastocytosis Programs
PR Newswire
May-12-20 11:36AM  
How Blueprint Medicines (BPMC) Stock Stands Out in a Strong Industry
Zacks
May-07-20 12:58PM  
Blueprint Medicines (BPMC) Q1 Earnings Top, Revenues Soar Y/Y
Zacks
08:01AM  
Blueprint Medicines (BPMC) Q1 2020 Earnings Call Transcript
Motley Fool
May-06-20 08:35AM  
Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates
Zacks
07:00AM  
Blueprint Medicines Reports First Quarter 2020 Financial Results
PR Newswire
Apr-28-20 11:19AM  
Blueprint Medicines Tumbles 20.8% on Phase 3 Study Failure
Motley Fool -17.31%
10:27AM  
P/E Ratio Insights for Blueprint Medicines
Benzinga
07:00AM  
Blueprint Medicines Announces Top-line Results from Phase 3 VOYAGER Trial of Avapritinib versus Regorafenib in Patients with Advanced Gastrointestinal Stromal Tumor
PR Newswire
Blueprint Medicines Corporation, a precision therapy company, develops transformative medicines for people with cancer and hematologic disorders, and multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy in the United States and Europe. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase 1b/2 trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib for the treatment of RET-altered non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945, a selective and potent investigational inhibitors of double-mutant EGFR harboring, which are in preclinical stage for patient with EGFR-driven NSCLC. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dorsch MarionChief Scientific OfficerFeb 22Option Exercise37.117,578281,22022,828Feb 24 04:28 PM
Dorsch MarionChief Scientific OfficerFeb 22Sale100.007,578757,80015,250Feb 24 04:28 PM
Demetri GeorgeDirectorJan 04Sale112.1575885,0103,562Jan 06 04:14 PM
Goldberg Mark AlanDirectorDec 24Option Exercise28.155,455153,5589,017Dec 28 04:23 PM
Goldberg Mark AlanDirectorDec 24Sale125.005,455681,8753,562Dec 28 04:23 PM
Goldberg Mark AlanDirectorDec 18Option Exercise28.155,454153,5309,016Dec 22 04:14 PM
Goldberg Mark AlanDirectorDec 18Sale120.005,454654,4803,562Dec 22 04:14 PM
Rowland Charles A JrDirectorDec 17Option Exercise19.5310,909213,05314,471Dec 18 04:09 PM
Rowland Charles A JrDirectorDec 17Sale117.8210,9091,285,2983,562Dec 18 04:09 PM
Albers Jeffrey W.CEO and PresidentDec 14Option Exercise8.805,00044,000146,434Dec 16 04:04 PM
Dorsch MarionChief Scientific OfficerDec 14Option Exercise37.114,600170,70619,850Dec 16 04:03 PM
Boral Anthony L.Chief Medical OfficerDec 14Option Exercise15.0110,000150,10038,147Dec 16 04:03 PM
Boral Anthony L.Chief Medical OfficerDec 14Sale118.5210,0001,185,20028,147Dec 16 04:03 PM
Dorsch MarionChief Scientific OfficerDec 14Sale119.004,600547,40015,250Dec 16 04:03 PM
Albers Jeffrey W.CEO and PresidentDec 14Sale119.185,000595,900141,434Dec 16 04:04 PM
Goldberg Mark AlanDirectorDec 11Option Exercise28.155,455153,5589,017Dec 15 04:08 PM
Goldberg Mark AlanDirectorDec 11Sale115.005,455627,3253,562Dec 15 04:08 PM
Hurley ArielPrincipal Accounting OfficerDec 01Option Exercise8.809007,92010,884Dec 03 04:10 PM
Goldberg Mark AlanDirectorDec 01Option Exercise28.155,454153,5309,016Dec 03 04:10 PM
Goldberg Mark AlanDirectorDec 01Sale110.005,454599,9403,562Dec 03 04:10 PM
Hurley ArielPrincipal Accounting OfficerDec 01Sale109.881,038114,0539,984Dec 03 04:10 PM
Hurley ArielPrincipal Accounting OfficerNov 16Option Exercise3.091,7005,25811,684Nov 18 04:21 PM
Albers Jeffrey W.CEO and PresidentNov 16Option Exercise8.8020,000176,000161,434Nov 18 04:22 PM
Haviland KateChief Operating OfficerNov 16Option Exercise36.0540914,74443,247Nov 18 04:23 PM
Haviland KateChief Operating OfficerNov 16Sale100.2740941,01042,838Nov 18 04:23 PM
Albers Jeffrey W.CEO and PresidentNov 16Sale98.7120,0001,974,295141,434Nov 18 04:22 PM
Hurley ArielPrincipal Accounting OfficerNov 16Sale100.921,700171,5649,984Nov 18 04:21 PM
Rowland Charles A JrDirectorNov 03Option Exercise9.465,52252,2389,084Nov 04 05:18 PM
Rowland Charles A JrDirectorNov 03Sale98.735,522545,1963,562Nov 04 05:18 PM
Rossi ChristinaChief Commercial OfficerNov 03Sale99.6934534,39320,020Nov 05 05:02 PM
Rowland Charles A JrDirectorNov 02Option Exercise9.464,47842,3628,040Nov 04 05:18 PM
Rowland Charles A JrDirectorNov 02Sale99.114,478443,8153,562Nov 04 05:18 PM
Boral Anthony L.Chief Medical OfficerOct 23Option Exercise12.709,183116,66728,147Oct 27 04:05 PM
Goldberg Mark AlanDirectorOct 19Option Exercise19.535,455106,5369,017Oct 21 04:21 PM
Goldberg Mark AlanDirectorOct 19Sale105.005,455572,7753,562Oct 21 04:21 PM
Haviland KateChief Operating OfficerOct 16Option Exercise36.0513,334480,69156,172Oct 20 04:09 PM
Haviland KateChief Operating OfficerOct 16Sale101.2313,3341,349,84842,838Oct 20 04:09 PM
Goldberg Mark AlanDirectorOct 07Option Exercise19.535,454106,5179,016Oct 09 04:04 PM
Albers Jeffrey W.CEO and PresidentOct 07Option Exercise8.805,00044,000146,434Oct 09 04:05 PM
Hurley ArielPrincipal Accounting OfficerOct 07Option Exercise8.806005,28010,584Oct 09 04:06 PM
Hurley ArielPrincipal Accounting OfficerOct 07Sale100.0060060,0009,984Oct 09 04:06 PM
Albers Jeffrey W.CEO and PresidentOct 07Sale99.175,000495,850141,434Oct 09 04:05 PM
Goldberg Mark AlanDirectorOct 07Sale100.005,454545,4003,562Oct 09 04:04 PM
Dorsch MarionChief Scientific OfficerOct 06Option Exercise37.114,600170,70619,850Oct 08 04:16 PM
Dorsch MarionChief Scientific OfficerOct 06Sale99.004,600455,40015,250Oct 08 04:16 PM
Lydon NicholasDirectorOct 01Sale93.089,815913,59537,425Oct 05 04:17 PM
Durso-Bumpus DebraChief People OfficerSep 23Option Exercise36.051,90068,49521,405Sep 25 04:26 PM
Dorsch MarionChief Scientific OfficerSep 23Option Exercise37.114,600170,70619,850Sep 25 04:27 PM
Hurley ArielPrincipal Accounting OfficerSep 23Option Exercise1.871,4002,61811,384Sep 25 04:27 PM
Hurley ArielPrincipal Accounting OfficerSep 23Sale90.001,400126,0009,984Sep 25 04:27 PM
Dorsch MarionChief Scientific OfficerSep 23Sale89.004,600409,40015,250Sep 25 04:27 PM
Durso-Bumpus DebraChief People OfficerSep 23Sale90.021,900171,03819,505Sep 25 04:26 PM
Haviland KateChief Operating OfficerSep 22Option Exercise16.283,14351,16845,981Sep 24 04:19 PM
Boral Anthony L.Chief Medical OfficerSep 22Option Exercise15.016,864103,02925,828Sep 24 04:22 PM
Demetri GeorgeDirectorSep 22Sale85.001,704144,8404,320Sep 24 04:22 PM
Boral Anthony L.Chief Medical OfficerSep 22Sale82.336,864565,11318,964Sep 24 04:22 PM
Haviland KateChief Operating OfficerSep 22Sale85.493,143268,69542,838Sep 24 04:19 PM
Boral Anthony L.Chief Medical OfficerSep 17Option Exercise11.4523,136264,94542,100Sep 21 04:22 PM
Boral Anthony L.Chief Medical OfficerSep 17Sale80.0023,1361,850,88018,964Sep 21 04:22 PM
Lydon NicholasDirectorSep 17Sale80.0050040,00047,240Sep 21 04:21 PM
Albers Jeffrey W.CEO and PresidentAug 19Option Exercise8.8020,000176,000161,434Aug 21 04:22 PM
Albers Jeffrey W.CEO and PresidentAug 19Sale75.0220,0001,500,438141,434Aug 21 04:22 PM
Hurley ArielPrincipal Accounting OfficerAug 17Option Exercise1.877001,30910,684Aug 19 04:52 PM
Hurley ArielPrincipal Accounting OfficerAug 17Sale75.0070052,5009,984Aug 19 04:52 PM
Lydon NicholasDirectorJul 06Sale80.4526,0072,092,35147,740Jul 08 04:25 PM
Lydon NicholasDirectorJul 02Sale80.132,825226,36773,747Jul 06 06:30 PM
Lydon NicholasDirectorJul 01Sale80.211,300104,27376,572Jul 06 06:30 PM
Lydon NicholasDirectorJun 23Sale80.0040032,00075,622Jun 25 04:10 PM
Durso-Bumpus DebraChief People OfficerJun 22Option Exercise36.052,30082,91521,805Jun 24 04:14 PM
Durso-Bumpus DebraChief People OfficerJun 22Sale80.072,300184,16119,505Jun 24 04:14 PM
Lydon NicholasDirectorJun 22Sale80.2913,0171,045,13576,022Jun 23 04:13 PM
Dorsch MarionChief Scientific OfficerJun 19Option Exercise37.114,600170,70619,850Jun 23 04:10 PM
Dorsch MarionChief Scientific OfficerJun 19Sale79.004,600363,40015,250Jun 23 04:10 PM
Durso-Bumpus DebraChief People OfficerJun 18Option Exercise18.002,50045,00022,005Jun 22 04:21 PM
Durso-Bumpus DebraChief People OfficerJun 18Sale75.182,500187,95019,505Jun 22 04:21 PM
Hurley ArielPrincipal Accounting OfficerJun 09Option Exercise1.877001,30910,684Jun 11 05:20 PM
Hurley ArielPrincipal Accounting OfficerJun 09Sale75.0070052,5009,984Jun 11 05:20 PM
Hurley ArielPrincipal Accounting OfficerJun 02Sale66.0323515,5179,984Jun 04 04:37 PM
Albers Jeffrey W.CEO and PresidentMay 12Option Exercise8.8020,000176,000161,434May 14 04:38 PM
Albers Jeffrey W.CEO and PresidentMay 12Sale64.6720,0001,293,427141,434May 14 04:38 PM
Albers Jeffrey W.CEO and PresidentMar 23Option Exercise5.3240,000212,846161,434Mar 25 04:22 PM
Albers Jeffrey W.CEO and PresidentMar 23Sale52.1020,0001,041,922141,434Mar 25 04:22 PM
Dorsch MarionChief Scientific OfficerMar 23Sale52.491,21463,72615,250Mar 25 04:22 PM
Hurley ArielPrincipal Accounting OfficerMar 09Sale51.9425313,1419,984Mar 11 04:32 PM
Boral Anthony L.Chief Medical OfficerMar 09Sale51.9753627,85618,964Mar 11 04:31 PM
Albers Jeffrey W.CEO and PresidentMar 09Sale51.972,277118,336121,434Mar 11 04:31 PM
Durso-Bumpus DebraChief People OfficerMar 09Sale51.9443222,43819,505Mar 11 04:30 PM
Dorsch MarionChief Scientific OfficerMar 09Sale51.9953627,86716,464Mar 11 04:30 PM
Landsittel MichaelChief Financial OfficerMar 09Sale51.9740020,78817,350Mar 11 04:29 PM
Haviland KateChief Operating OfficerMar 09Sale51.9867134,87942,838Mar 11 04:29 PM
Rossi ChristinaChief Commercial OfficerMar 09Sale51.961357,01520,365Mar 11 04:27 PM
Murray Christopher K.SVP, Technical OperationsMar 09Sale51.9440220,88013,848Mar 11 04:28 PM
McCain Tracey LEVP and Chief Legal OfficerMar 09Sale51.9861732,07221,683Mar 11 04:28 PM
open in yahoo | open in reuters | open in google
affiliate • advertise • contact • privacy • help
Do not sell my personal information
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2021 FINVIZ.com. All Rights Reserved.